CSA Medical touts QoL improvements in RejuvenAir chronic bronchitis study

CSA Medical today released early results from a feasibility study exploring the use of its RejuvenAir Metered Cryospray system in treating patients with chronic bronchitis, touting improvements in quality of life for patients treated with the system. Results from the trial were presented at the 2018 European Respiratory Society Congress in Paris, the Boston-based company said. “We are encouraged by these positive safety and feasibility results and we’re moving forward with plans to initiate a worldwide pivotal study of RejuvenAir in chronic bronchitis in 2019. We look forward to advancing this novel therapy toward commercialization to provide relief to the millions of patients suffering from COPD with chronic bronchitis,” chief commercial officer Wendelin Maners said in a prepared statement. Data came from an analysis of 30 patients during their six-month follow-up visits, and indicated improvements in quality of life, as measured by Saint George’s Respiratory Questionnaire and COPD Assessment Test. Results also indicated a strong safety profile, and that the treatment was well tolerated, CSA Medical said. Patients saw an average improvement on average of 10.9 points on the SGRQ, with an improvement of four points on the scale considered to be clinically meaningful, the company said. Average improvements on the CAT were reported to be 3.4 points at six months, with improvements of two points considered clinically meaningful, the company added. “...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Respiratory CSA Medical Inc. Source Type: news